ASCO 2023 | 一文快速网罗肝癌领域重要研究

我们整理了肝癌领域海报会议、海报讨论会 、临床科学研讨会、口头摘要会议的研究，与读者分享。 

1.海报讨论会议

新辅助肝动脉输注化疗FOLFOX可以改善可切除的BCLC A/B期肝癌患者的预后，超出米兰标准:一项多中心，3期随机对照临床试验。

Neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: A multi-center, phase 3, randomized, controlled clinical trial.

第一作者：Wei Wei

摘要号：4023

评估TTI-1（一种首创的口服生物可利用小分子STAT101抑制剂）治疗晚期实体瘤患者的3期试验。

Phase 1 trial evaluating TTI-101, a first-in-class, orally bioavailable, small molecule, inhibitor of STAT3, in patients with advanced solid tumors.

第一作者：Apostolia Maria Tsimberidou

摘要号：3018

2.海报会议

在既往抗PD-（L）1阻断后，挽救伊匹木单抗加纳武利尤单抗治疗晚期肝细胞癌。

Salvage ipilimumab plus nivolumab in advanced hepatocellular carcinoma after prior anti-PD-(L)1 blockade.

第一作者：Stephanie Leigh Alden

摘要号：4091

经动脉化疗栓塞联合仑伐替尼和卡瑞珠单抗治疗不可切除的肝细胞癌：一项前瞻性、单臂、多中心研究。

Transarterial chemoembolization combined with lenvatinib and camrelizumab for unresectable hepatocellular carcinoma: A prospective, single-arm, multicenter study.

第一作者：Zhibo Zhang

摘要号：4072

度伐利尤单抗和tremelimumab用于肝移植患者的肝细胞癌。

Durvalumab and tremelimumab for hepatocellular carcinoma in patients listed for a liver transplant.

第一作者：Davendra Sohal

摘要号：TPS4188

IBI110与信替利单抗和仑伐替尼联合治疗晚期肝细胞癌一线治疗的有效性和安全性：Ib期研究的初步结果。

Efficacy and safety of IBI110 in combination with sintilimab and lenvatinib in first-line of advanced hepatocellular carcinoma: Preliminary results from a phase Ib study.

第一作者：Ming Liu

摘要号：2577

卡瑞利珠单抗联合阿帕替尼作为复发风险高的肝细胞癌患者的围手术期治疗：一项前瞻性、单臂、2 期研究。

Camrelizumab in combination with apatinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: A prospective, single-arm, phase 2 study.

第一作者：Yunlong Cui

摘要号：4120

NeoTACE：一项多中心随机研究，评估新辅助 HAIC 治疗 TACE 加多纳非尼治疗 BCLC B 期肝细胞癌的有效性和安全性

NeoTACE: A multicenter, randomized study evaluating the efficacy and safety of neoadjuvant HAIC for TACE plus donafenib in BCLC B stage hepatocellular carcinoma outside of up-to-seven.

第一作者：Xiaodong Wang

摘要号：TPS4186

NMS-01940153E（一种具有同类首创潜力的MPS1抑制剂）在既往接受全身治疗的不可切除肝细胞癌（HCC）成年患者中的安全性和有效性的II期研究。

Phase II study on safety and efficacy of NMS-01940153E, an MPS1 inhibitor with first-in-class potential, in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy.

第一作者：Lorenza Rimassa

摘要号：TPS4185

一项开放标签的多中心研究，研究 RP3 溶瘤免疫治疗联合一线或二线全身性阿替利珠单抗和贝伐珠单抗治疗局部晚期不可切除或转移性肝细胞癌患者。

An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab and bevacizumab therapy in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.

第一作者：Tanios S. Bekaii-Saab

摘要号：TPS4187

卡瑞珠单抗加阿帕替尼作为中高风险可切除肝细胞癌围手术期治疗的 II/III 期研究：II 期主要病理反应的主要结果。

A phase II/III study of camrelizumab plus apatinib as perioperative treatment of resectable hepatocellular carcinoma at intermediate-high risk of recurrence: Primary results of major pathologic response from phase II stage.

第一作者：Jian Zhou

摘要号：4126

仑伐替尼（LEN）联合替雷利珠单抗（TIS）加经导管动脉化疗栓塞术（TACE）治疗不可切除的肝细胞癌（uHCC）：一项单臂II期临床试验。

Lenvatinib (LEN) combined with tislelizumab (TIS) plus transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II clinical trial.

第一作者：Xiang Nong

摘要号：4111

在局部晚期、不可切除的肝细胞癌中使用单曲霉素定期间隔度伐利尤单抗进行序贯经动脉化疗栓塞和立体定向放疗，然后使用单曲霉素定期间隔度伐利尤单抗进行免疫治疗的初步结果（START-FIT 使用 STRIDE）：一项单臂 II 期研究。

Preliminary results of sequential transarterial chemoembolization and stereotactic body radiotherapy followed by immunotherapy using single tremelimumab regular interval durvalumab in locally advanced, unresectable hepatocellular carcinoma (START-FIT using STRIDE): A single-arm, phase II study.

第一作者：Chi Leung Chiang

摘要号：4124

VG2025（一种表达IL-1和IL-12 / RA有效载荷的非减毒HSV-15溶瘤病毒）在晚期实体瘤患者中的I期试验的初步报告。

The initial report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors.

第一作者：Siqing Fu

摘要号：2580

度伐利尤单抗（MEDI4736）联合/不联合tremelimumab治疗姑息性大分割放疗后晚期肝细胞癌的II期试验。

Phase II trial of durvalumab (MEDI4736) with/without tremelimumab for advanced hepatocellular carcinoma after palliative hypofractionated radiotherapy.

第一作者：Luchia Andemicael，加州大学旧金山分校，加利福尼亚州旧金山;

摘要号：TPS630

腹腔热化疗联合替雷利珠单抗和靶向治疗 R0 切除术后高危肝细胞癌的 II 期试验。

A phase II trial of hyperthermic intraperitoneal chemotherapy combined with tislelizumab and targeted therapy in high-risk hepatocellular carcinoma after R0 resection.

第一作者：Sulai Liu，湖南省人民医院肝胆外科，湖南师范大学第一附属医院，长沙

摘要号：TPS635

3.口头摘要会议

在喜马拉雅不可切除肝细胞癌（uHCC）的3期喜马拉雅研究中，使用tremelimumab（T）加durvalumab（D）发生的免疫介导不良事件（imAEs）的结果。

Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).

第一作者：George Lau

摘要号：4004

在切除或消融后疾病复发风险高的肝细胞癌（HCC）患者中，辅助阿替利珠单抗（atezo）+贝伐珠单抗（BEV）与主动监测的III期IMbrave050试验的有效性、安全性和患者报告结局（PROs）。

Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation.

第一作者：Masatoshi Kudo

摘要号：4002

4.临床科学研讨会

粪便微生物群移植联合抗PD-1抑制剂治疗抗PD-1抑制剂难治的不可切除或转移性实体癌。

Fecal microbiota transplantation combined with anti-PD-1 inhibitor for unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor.

第一作者：Sook Ryun Park

摘要号：105

MORPHEUS-肝脏研究的结果：tiragolumab（tira）联合阿替利珠单抗（atezo）和贝伐珠单抗（bev）在不可切除的局部晚期或转移性肝细胞癌（uHCC）患者中的Ib/II期随机评估。

Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC).

第一作者：Richard S. Finn

摘要号：4010

声明：本资料中涉及的信息仅供参考，请遵从医生或其他医疗卫生专业人士的意见或指导。

打赏